- Home
- PEPG vs ALXO Comparison
PEPG vs ALXO Comparison
Compare PEPG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- ALXO
- Stock Information
- Founded
- PEPG 2018
- ALXO 2015
- Country
- PEPG United States
- ALXO United States
- Employees
- PEPG N/A
- ALXO N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- ALXO Health Care
- Exchange
- PEPG Nasdaq
- ALXO Nasdaq
- Market Cap
- PEPG 64.2M
- ALXO 76.5M
- IPO Year
- PEPG 2022
- ALXO 2020
- Fundamental
- Price
- PEPG $1.37
- ALXO $1.12
- Analyst Decision
- PEPG Buy
- ALXO Buy
- Analyst Count
- PEPG 3
- ALXO 6
- Target Price
- PEPG $14.67
- ALXO $6.64
- AVG Volume (30 Days)
- PEPG 486.5K
- ALXO 775.3K
- Earning Date
- PEPG 03-05-2025
- ALXO 03-06-2025
- Dividend Yield
- PEPG N/A
- ALXO N/A
- EPS Growth
- PEPG N/A
- ALXO N/A
- EPS
- PEPG N/A
- ALXO N/A
- Revenue
- PEPG N/A
- ALXO N/A
- Revenue This Year
- PEPG N/A
- ALXO N/A
- Revenue Next Year
- PEPG N/A
- ALXO N/A
- P/E Ratio
- PEPG N/A
- ALXO N/A
- Revenue Growth
- PEPG N/A
- ALXO N/A
- 52 Week Low
- PEPG $1.16
- ALXO $0.96
- 52 Week High
- PEPG $19.30
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- PEPG 31.82
- ALXO 38.53
- Support Level
- PEPG $1.16
- ALXO $1.00
- Resistance Level
- PEPG $1.60
- ALXO $1.22
- Average True Range (ATR)
- PEPG 0.14
- ALXO 0.09
- MACD
- PEPG 0.11
- ALXO 0.00
- Stochastic Oscillator
- PEPG 48.28
- ALXO 35.12
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.